A phase II trial of maintenance rucaparib in 42 germline pathogenic BRCA1/BRCA2 and PALB2 mutant (2 patients with somatic BRCA2 mutations were also included) advanced pancreatic cancer patients who had received platinum-based chemotherapy without evidence of progression disclosed a median PFS of 13.1 months (95% CI: 4.4–21.8 months) and a median OS of 23.5 months (95% CI: 20–27 months) [59]. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.